nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.02.2014 | Original Article

Test–retest reliability of [¹¹C]AZ10419369 binding to 5-HT_1B receptors in human brain

verfasst von: Magdalena Nord, Sjoerd J. Finnema, Martin Schain, Christer Halldin, Lars Farde

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

[¹¹C]AZ10419369 is a recently developed 5-HT_1B receptor radioligand that is sensitive to changes in endogenous serotonin concentrations in the primate brain. Thus, [¹¹C] AZ10419369 may serve as a useful tool in clinical studies of the pathophysiology and pharmacological treatment of diseases related to the serotonin system, such as depression and anxiety disorders. The aim of this study was to evaluate the test–retest reliability of [¹¹C]AZ10419369.

Methods

Eight men were examined with PET and [¹¹C] AZ10419369 twice on the same day. The binding potentials (BP_ND) of [¹¹C]AZ10419369 in selected serotonergic projection areas and in the raphe nuclei (RN) were determined using the simplified reference tissue model, and for comparison also using a wavelet-aided parametric imaging approach. The BP_ND values obtained from the first and second PET scans were compared by means of descriptive statistics, difference, absolute variability and intraclass correlation coefficient.

Results

Similar BP_ND values were obtained with the two methods. The absolute mean differences in BP_ND between PET 1 and PET 2 were less than 3 % in all serotonergic projection regions. Absolute variabilities were low in cortical regions (5 – 7 %), low to moderate (7 – 14 %) in subcortical regions, but higher (20 %) in the RN.

Conclusion

The BP_ND of [¹¹C]AZ10419369 is highly reproducible in cortical regions and satisfactory in subcortical projection areas. The variability in the RN is higher. Thus larger sample sizes or larger divergences are required to assess a potential difference between subjects or between experimental conditions in this region.

Nur mit Berechtigung zugänglich

Sari Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004;28:565–82.PubMedCrossRef

Ruf BM, Bhagwagar Z. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets. 2009;10:1118–38.PubMedCrossRef

Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol. 2002;9 Suppl 3:1–6.PubMedCrossRef

Varnas K, Jucaite A, McCarthy DJ, Stenkrona P, Nord M, Halldin C, et al. A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers. Cephalalgia. 2013;33:853–60.PubMedCrossRef

Varnas K, Hall H, Bonaventure P, Sedvall G. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [3H]GR 125743. Brain Res. 2001;915:47–57.PubMedCrossRef

Varnas K, Hurd YL, Hall H. Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse. 2005;56:21–8.PubMedCrossRef

Adell A, Celada P, Artigas F. The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem. 2001;79:172–82.PubMedCrossRef

Varnas K, Nyberg S, Halldin C, Varrone A, Takano A, Karlsson P, et al. Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab. 2011;31:113–23.PubMedCrossRef

Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnas K, et al. [11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage. 2008;41:1075–85.PubMedCrossRef

10.

Andersson JD, Pierson ME, Finnema SJ, Gulyas B, Heys R, Elmore CS, et al. Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. Nucl Med Biol. 2011;38:261–72.PubMedCrossRef

11.

Finnema SJ, Varrone A, Hwang TJ, Gulyas B, Pierson ME, Halldin C, et al. Fenfluramine-induced serotonin release decreases [11C]AZ10419369 binding to 5-HT(1B)-receptors in the primate brain. Synapse. 2010;64:573–7.PubMedCrossRef

12.

Nord M, Finnema SJ, Halldin C, Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int J Neuropsychopharmacol. 2013;16:1577–86.PubMedCrossRef

13.

Finnema SJ, Varrone A, Hwang TJ, Halldin C, Farde L. Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [11C]AZ10419369 using an equilibrium approach. J Cereb Blood Flow Metab. 2012;32:685–95.PubMedCrossRef

14.

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;20(59 Suppl):22–33; quiz 4–57.PubMed

15.

Derry C, Benjamin C, Bladin P, le Bars D, Tochon-Danguy H, Berkovic SF, et al. Increased serotonin receptor availability in human sleep: evidence from an [18F]MPPF PET study in narcolepsy. Neuroimage. 2006;30:341–8.PubMedCrossRef

16.

Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639–50.PubMedCrossRef

17.

Schain M, Toth M, Cselenyi Z, Stenkrona P, Halldin C, Farde L, et al. Quantification of serotonin transporter availability with [11C] MADAM – a comparison between the ECAT HRRT and HR systems. Neuroimage. 2012;60:800–7.PubMedCrossRef

18.

Bonaventure P, Schotte A, Cras P, Leysen JE. Autoradiographic mapping of 5-HT1B- and 5-HT1D receptors in human brain using [3H]alniditan, a new radioligand. Receptors Channels. 1997;5:225–30.PubMed

19.

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.PubMedCrossRef

20.

Cselenyi Z, Olsson H, Farde L, Gulyas B. Wavelet-aided parametric mapping of cerebral dopamine D2 receptors using the high affinity PET radioligand [11C]FLB 457. Neuroimage. 2002;17:47–60.PubMedCrossRef

21.

McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30–46.CrossRef

22.

Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.PubMedCrossRef

23.

Alakurtti K, Aalto S, Johansson JJ, Nagren K, Tuokkola T, Oikonen V, et al. Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J Cereb Blood Flow Metab. 2011;31:155–65.PubMedCrossRef

24.

Lundberg J, Halldin C, Farde L. Measurement of serotonin transporter binding with PET and [11C]MADAM: a test-retest reproducibility study. Synapse. 2006;60:256–63.PubMedCrossRef

25.

Hirvonen J, Kajander J, Allonen T, Oikonen V, Nagren K, Hietala J. Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635 – considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab. 2007;27:185–95.PubMedCrossRef

26.

Jovanovic H, Cerin A, Karlsson P, Lundberg J, Halldin C, Nordstrom AL. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res. 2006;148:185–93.PubMedCrossRef

27.

Paterson LM, Kornum BR, Nutt DJ, Pike VW, Knudsen GM. 5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev. 2013;33:54–111.PubMedCrossRef

28.

Selvaraj S, Turkheimer F, Rosso L, Faulkner P, Mouchlianitis E, Roiser JP, et al. Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. Mol Psychiatry. 2012;17:1254–60.PubMedCrossRef

Titel: Test–retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain
verfasst von: Magdalena Nord
Sjoerd J. Finnema
Martin Schain
Christer Halldin
Lars Farde
Publikationsdatum: 01.02.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2529-1

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT

Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study

Improving the dose–myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP

Good clinical practice in pulmonary embolism diagnosis: where do we stand today?

EJNMMI Physics—Access is open for open access

Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels